vs
FNB CORP（FNB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
FNB CORP的季度营收约是Ultragenyx Pharmaceutical Inc.的1.8倍（$366.0M vs $207.3M），FNB CORP净利率更高（45.9% vs -62.0%，领先107.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 13.7%），FNB CORP自由现金流更多（$99.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.1%）
FNB集团是总部位于美国宾夕法尼亚州匹兹堡的多元化金融服务机构，为旗下最大子公司第一国民银行的控股主体，截至2025年12月31日总资产超500亿美元，业务覆盖匹兹堡、巴尔的摩、克利夫兰、华盛顿特区、北卡罗来纳州多座城市及南卡罗来纳州查尔斯顿等核心都会区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FNB vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $366.0M | $207.3M |
| 净利润 | $168.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 45.1% | -54.7% |
| 净利率 | 45.9% | -62.0% |
| 营收同比 | 13.7% | 25.9% |
| 净利润同比 | 52.7% | 3.5% |
| 每股收益（稀释后） | $0.47 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $366.0M | $207.3M | ||
| Q3 25 | $359.0M | $159.9M | ||
| Q2 25 | $348.0M | $166.5M | ||
| Q1 25 | $323.0M | $139.3M | ||
| Q4 24 | $322.0M | $164.6M | ||
| Q3 24 | $323.0M | $139.5M | ||
| Q2 24 | $316.0M | $147.0M | ||
| Q1 24 | $319.0M | $108.8M |
| Q4 25 | $168.0M | $-128.6M | ||
| Q3 25 | $150.0M | $-180.4M | ||
| Q2 25 | $130.0M | $-115.0M | ||
| Q1 25 | $117.0M | $-151.1M | ||
| Q4 24 | $110.0M | $-133.2M | ||
| Q3 24 | $110.0M | $-133.5M | ||
| Q2 24 | $123.0M | $-131.6M | ||
| Q1 24 | $122.0M | $-170.7M |
| Q4 25 | 45.1% | -54.7% | ||
| Q3 25 | 52.9% | -106.9% | ||
| Q2 25 | 47.7% | -64.8% | ||
| Q1 25 | 45.8% | -102.6% | ||
| Q4 24 | 31.7% | -74.3% | ||
| Q3 24 | 43.3% | -94.6% | ||
| Q2 24 | 49.7% | -79.1% | ||
| Q1 24 | 48.9% | -151.9% |
| Q4 25 | 45.9% | -62.0% | ||
| Q3 25 | 41.8% | -112.8% | ||
| Q2 25 | 37.4% | -69.0% | ||
| Q1 25 | 36.2% | -108.5% | ||
| Q4 24 | 34.2% | -80.9% | ||
| Q3 24 | 34.1% | -95.7% | ||
| Q2 24 | 38.9% | -89.5% | ||
| Q1 24 | 38.2% | -156.8% |
| Q4 25 | $0.47 | $-1.28 | ||
| Q3 25 | $0.41 | $-1.81 | ||
| Q2 25 | $0.36 | $-1.17 | ||
| Q1 25 | $0.32 | $-1.57 | ||
| Q4 24 | $0.31 | $-1.34 | ||
| Q3 24 | $0.30 | $-1.40 | ||
| Q2 24 | $0.34 | $-1.52 | ||
| Q1 24 | $0.32 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5B | $421.0M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $6.8B | $-80.0M |
| 总资产 | $50.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
| Q4 25 | $2.5B | $421.0M | ||
| Q3 25 | $2.4B | $202.5M | ||
| Q2 25 | $2.4B | $176.3M | ||
| Q1 25 | $2.4B | $127.1M | ||
| Q4 24 | $2.4B | $174.0M | ||
| Q3 24 | $2.1B | $150.6M | ||
| Q2 24 | $1.9B | $480.7M | ||
| Q1 24 | $1.5B | $112.3M |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.7B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | $6.8B | $-80.0M | ||
| Q3 25 | $6.6B | $9.2M | ||
| Q2 25 | $6.5B | $151.3M | ||
| Q1 25 | $6.4B | $144.2M | ||
| Q4 24 | $6.3B | $255.0M | ||
| Q3 24 | $6.2B | $346.8M | ||
| Q2 24 | $6.1B | $432.4M | ||
| Q1 24 | $6.0B | $140.3M |
| Q4 25 | $50.2B | $1.5B | ||
| Q3 25 | $49.9B | $1.2B | ||
| Q2 25 | $49.7B | $1.3B | ||
| Q1 25 | $49.0B | $1.3B | ||
| Q4 24 | $48.6B | $1.5B | ||
| Q3 24 | $48.0B | $1.5B | ||
| Q2 24 | $47.7B | $1.6B | ||
| Q1 24 | $45.9B | $1.3B |
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.32× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.39× | — | ||
| Q4 24 | 0.48× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $128.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 27.0% | -48.6% |
| 资本支出强度资本支出/营收 | 7.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.76× | — |
| 过去12个月自由现金流最近4个季度 | $376.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $128.0M | $-99.8M | ||
| Q3 25 | $167.0M | $-91.4M | ||
| Q2 25 | $123.0M | $-108.3M | ||
| Q1 25 | $64.0M | $-166.5M | ||
| Q4 24 | $326.0M | $-79.3M | ||
| Q3 24 | $-14.0M | $-67.0M | ||
| Q2 24 | $85.0M | $-77.0M | ||
| Q1 24 | $245.0M | $-190.7M |
| Q4 25 | $99.0M | $-100.8M | ||
| Q3 25 | $149.0M | $-92.7M | ||
| Q2 25 | $85.0M | $-110.7M | ||
| Q1 25 | $43.0M | $-167.8M | ||
| Q4 24 | $278.0M | $-79.5M | ||
| Q3 24 | $-46.0M | $-68.6M | ||
| Q2 24 | $55.0M | $-79.0M | ||
| Q1 24 | $216.0M | $-193.9M |
| Q4 25 | 27.0% | -48.6% | ||
| Q3 25 | 41.5% | -58.0% | ||
| Q2 25 | 24.4% | -66.5% | ||
| Q1 25 | 13.3% | -120.5% | ||
| Q4 24 | 86.3% | -48.3% | ||
| Q3 24 | -14.2% | -49.2% | ||
| Q2 24 | 17.4% | -53.7% | ||
| Q1 24 | 67.7% | -178.2% |
| Q4 25 | 7.9% | 0.5% | ||
| Q3 25 | 5.0% | 0.8% | ||
| Q2 25 | 10.9% | 1.5% | ||
| Q1 25 | 6.5% | 1.0% | ||
| Q4 24 | 14.9% | 0.1% | ||
| Q3 24 | 9.9% | 1.2% | ||
| Q2 24 | 9.5% | 1.4% | ||
| Q1 24 | 9.1% | 3.0% |
| Q4 25 | 0.76× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 2.96× | — | ||
| Q3 24 | -0.13× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 2.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNB
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
